Lantarel Fs (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the growth of rapidly dividing cells, including immune cells involved in inflammation and malignant cells in certain cancers.

The dose of Lantarel Fs is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No fixed dosing regimen is provided here; the prescriber sets the appropriate amount.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal malformations or death. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To order Lantarel Fs, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other disease‑modifying agents, methotrexate offers a well‑established efficacy profile for autoimmune diseases and certain cancers at a relatively low cost. Biologic agents may provide targeted action but are generally more expensive and require subcutaneous or intravenous infusion, whereas methotrexate can be given by multiple injection routes.

Lantarel Fs should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product to maintain stability.

Lantarel Fs is supplied as an injectable solution and may be given intramuscularly, intravenously, or subcutaneously according to the prescriber’s instructions. Administration technique follows standard aseptic injection practices.

Serious risks include severe liver toxicity (hepatitis or fibrosis), pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and teratogenic effects that can cause fetal malformations. Patients should be monitored regularly for liver function, blood counts and respiratory symptoms.

Lantarel Fs should not be used by pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe renal or hepatic impairment, and those receiving live vaccines without medical supervision. Contraindications are determined by the treating physician.